References
- Raben D, Bianco C, Milas L, Ang KK. Targeted therapies and radiation for the treatment of head and neck cancer: Arewe making progress? Semin. Radiat. Oncol 2004;14:139-152
- Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-7356
- Grandis JR, Melhem MF, Barnes EL, et al. Quantitative immunohistochemical analysis of transforming growth factorand epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996;78:1284-1292 https://doi.org/10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X
- Grandis J, Tweardy D. Elevated levels of transforming growth factor and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-3584
- O-Charoenrat P, Rhys-Evans P, Eccles S. Expression and regulation of c-ERBB ligands in human head and neck squamous carcinoma cells. Int J Cancer 2000;88:759-765 https://doi.org/10.1002/1097-0215(20001201)88:5<759::AID-IJC12>3.0.CO;2-0
- Sheridan MT, O'Dwyer T, Seymour CB, et al. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Invest 1997;5:180-186 https://doi.org/10.1002/(SICI)1520-6823(1997)5:4<180::AID-ROI3>3.0.CO;2-U
- Akimoto T, Hunter NR, Buchmiller L, et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999;5:437-443
- Gupta AK, McKenna WG, Weber CN, et al. Local recurrence in head and neck cancer: Relationship to radiation resistance and signal transduction. Clin Cancer Res 2002;8: 885-892
- Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11: 1873-1878 https://doi.org/10.1200/JCO.1993.11.10.1873
- Grandis J, Melhem M, Gooding W, et al. Levels of TGFand EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-832 https://doi.org/10.1093/jnci/90.11.824
- Hendler F, Shum-Siu A, Nanu L, et al. Overexpression of EGF receptors in squamous tumors is associated with poor survival. J Cell Biochem 1988;12:105
- Miyaguchi M, Olofosson J, Hellquist HB. Expression of epidermal growth factor receptor in glottic carcinoma and its relation to recurrence after radiotherapy. Clin Otolaryngol 1991;16:466-469 https://doi.org/10.1111/j.1365-2273.1991.tb01041.x
- Wen QH, Miwa T, Yoshizaki T, et al. Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy. Laryngoscope 1996;106:884-888 https://doi.org/10.1097/00005537-199607000-00019
- Maurizi M, Almadori G, Ferrandina G, et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 1996;74:1253-1257 https://doi.org/10.1038/bjc.1996.525
- Craven JM, Pavelic ZP, Stambrook PJ, et al. Expression of c-erbB-2 gene in human head and neck carcinoma. Anticancer Res 1992;12:2273-2276
- Beckhardt RN, Kiyokawa N, Xi L, et al. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1995;121: 1265-1270 https://doi.org/10.1001/archotol.1995.01890110041008
- Field JK, Spandidos DA, Yiagnisis M, et al. C-erbB-2 expression in squamous cell carcinoma of the head and neck. Anticancer Res 1992;12:613-619
- Xia W, Lau Y, Zhang H, et al. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 1997;3:3-9
- Shintani S, Funaymam T, Yoshihama Y, et al. Prognostic significance of ERRB3 overexpression in oral squamous cell carcinoma. Cancer Letters 1995;95:79-83 https://doi.org/10.1016/0304-3835(95)03866-U
- Xia W, Lau YK, Zhang HZ, et al. Combination of EGFR, HER-2/neu and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999;5:4164-417
- Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997;3:2703-2707
- Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166-2174
- Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59:1935-1940
- Huang SM, Li J, Harari PM. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 2002;1:507-514
- Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 1997;89:341- 343 https://doi.org/10.1093/jnci/89.5.341
- Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-2970
- Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: A fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 2002;29:47-50
- Dent P, Reardon DB, Park JS, et al. Radiation-induced release of transforming growth factor a activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999;10:2493-2506 https://doi.org/10.1091/mbc.10.8.2493
- Motoyama A, Hynes NE, Lane HA. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 2002;62:3151-3158
- Grandis JR, Drenning SD, Chakraborty A, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth In vitro. J Clin Invest 1998;102:1385-1392 https://doi.org/10.1172/JCI3785
- Sriuranpong V, Park JI, Amornphimoltham P, et al. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 2003;63:2948- 2956
- Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999;291:739-748
- Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacological study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-3279 https://doi.org/10.1200/JCO.2001.19.13.3267
- Senzer N, Soulieres D, Siu L, et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc ASCO 2001;20:2a
- Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-4302 https://doi.org/10.1200/JCO.2002.03.100
- Shin DM, Nemunaitis J, Zinner RG, et al. A phase I clinical and biomarker study of CI-1033, a novel Pan-ErbB tyrosine kinase inhibitor in patients with solid tumors. Proc ASCO 2001;20:82a
- Garrison MA, Tolcher A, McCreery H, et al. A phase I and pharmacokinetic study of CI-1003, a Pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8 and 15 Every 28 days to patients with solid tumors. Proc ASCO 2001;20:72a
- Vanhoefer U, Tewes M, Rojo F, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD7200 in patients with advanced solid tumors that express the epidermal growth factor. J Clin Oncol 2004;22:175-184 https://doi.org/10.1200/JCO.2004.05.114
- Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-3243 https://doi.org/10.1200/JCO.2001.19.13.3234
- Pfister DG, Aliff TB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiation therapy (RT) for locoregionally advanced, squamous cell head and neck cancer (SCCHN): Preliminary evaluation of a new combinedmodality paradigm. Proc ASCO 2003;22:495
- Ciardiello F, Caputo R, Bianco R, et al. Antitumor effects and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptorselective tyrosine kinase inhibitor. Clin Cancer Res 2000;6: 2053-2063
- Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-4892
- Saijo N, Nishio K, Tamura T. Translational and clinical studies of target-based cancer therapy. Int J Clin Oncol 2003; 8:187-192 https://doi.org/10.1007/s10147-003-0324-x
- Eberhard A, Kahlert S, Goede V, et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies. Cancer Res 2000;60:1388-1393
- Sonveaux P, Brouet A, Havaux X, et al. Irradiationinduced angiogenesis through the up-regulation of the nitric oxide pathway: Implications for tumor radiotherapy. Cancer Res 2003;63:1012-1019
- Teicher B, Depuis NP, Kusumoto T, et al. Anti-angiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Invest 1995;2:269-276 https://doi.org/10.1002/roi.2970020604
- Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-4655
- Williams KJ, Telfer BA, Stratford IJ, et al. ZD6474, a potent inhibitor of VEGF signaling, combined with radio-therapy: Schedule-dependent enhancement of anti-tumor activity in a lung tumor xenograft model. Proc AACR 2003;44:9
- Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;53:164-171 https://doi.org/10.1016/S0360-3016(02)02742-6
- Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 2001;61:5090-5101
- ung YD, Mansfield MA, Akagi M, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002;38:1133-1140 https://doi.org/10.1016/S0959-8049(02)00013-8
- Ciardiello F, Caputo R, Bianco R, et al. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. JNCI Cancer Spectrum 1998;90:1087-1094
- Patel V, Senderowicz AM, Pinto D Jr, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 1998;102:1674-1681
- Mihara M, Shintani S, Nakashiro K, et al. Flavopiridol, a cyclin dependent kinase (CDK) inhibitor, induces apoptosis by regulating Bcl-x in oral cancer cells. Oral Oncol 2003;39:49-5 https://doi.org/10.1016/S1368-8375(02)00019-2
- Taguchi F, Koh Y, Koizumi F, et al. Activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR (KDR)-TKI), in a model of ZD1839 (Iressa) resistance. Proc AACR 2003;44:1119
- Matar P, Rojo R, Guzman M, et al. Combined anti- epidermal growth factor receptor (EGFR) treatment with a tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) and a monoclonal antibody (IMC-C225): Evidence of synergy. Proc AACR 2003; 44:917
- Baselga J. A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization. Cancer Cell 2002;2:93-95 https://doi.org/10.1016/S1535-6108(02)00098-3
- Kies MS, Clayman GL, El-Naggar AK, et al. Induction therapy with SCH 66336, a farnesyl transferase inhibitor, in squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 2001;20:896
- Kim ES, Glisson BS, Meyers ML, et al. A phase I/II study of the farnesyl transferase inhibitor (FTI) SCH 66336 with paclitaxel in patients with solid tumors. Proc Am Assoc Cancer Res 2001;42:2629
- Haddad RI, Shapiro GI, Weinstein L, et al. A phase II study of E7070 in patients with metastatic, recurrent, or refractory head and neck squamous cell carcinoma (HNSCC): clinical activity and post-treatment modulation of Rb phosphorylation. Proc Am Soc Clin Oncol 2003;22:800
- Moon C, Oh Y, Roth JA. Current status of gene therapy for lung cancer and head and neck cancer. Clin Cancer Res 2003; 9:5055-5067 62. Lebowitz PF, Harkins C, Conley B, et al. Concomitant therapy with proteasome inhibitor, bortezomib, and radiation in patients with recurrent or metastatic head and neck squamous cell carcinoma. Proc Am Soc Clin Oncol 2003;22:2010 (abstr)